8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 30, 2009

ENCISION, INC.

(Exact name of registrant as specified in its charter)

Colorado	0-28604	84-1162056
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

6797 Winchester Circle, Boulder, Colorado	80301
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code (303) 444-2600

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

The following information is furnished pursuant to Item 2.02, “Results of Operations and Financial Condition,” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

On July 30, 2009, ENCISION, INC., issued a press release announcing its financial results for the first quarter ended June 30, 2009.  A copy of the press release is attached hereto as Exhibit 99.1.

The information contained in this Current Report, including the exhibit, shall not be incorporated by reference into any filing of ENCISION, INC., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)           Exhibits.

99.1 Press Release issued by ENCISION, INC., July 30, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ENCISION, INC. (Registrant)
Date July 30, 2009	By:	/s/ Marcia K. McHaffie
		Marcia K. McHaffie
		Controller
		Principal Accounting Officer

EX-99.1

Exhibit 99.1

Encision Reports Profitable First Fiscal Quarter Results

BOULDER, Colo., July 30 /PRNewswire-FirstCall/ -- Encision Inc. (OTC Bulletin Board: ECIA), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported its financial results for its first quarter of fiscal year 2010.

Net sales for the three-months ended June 30, 2009 totaled $3.2 million, representing a 3% increase over net sales of $3.1 million for the prior fiscal year’s first quarter. The Company recorded net income of $163 thousand or $.03 per share for the first quarter of fiscal year 2010, compared to a net loss of $164 thousand or ($.03) per share for the first quarter of fiscal year 2009. Gross profit margin for the first quarter of fiscal year 2010 was 64%, as compared to 60.3% for the first quarter of fiscal year 2009, a 3.7% increase resulting from production efficiencies and an increase to inventory which resulted in a higher absorption of overhead costs to inventory and a decrease to cost of sales.

“We are pleased with the start to our first quarter of fiscal year 2010, especially with the turnaround from last year’s first quarter net loss. Net income increased from last year’s first quarter net loss as a result of a slight increase in sales income, increased gross profit margin and reduced operating expenses,” said Jack Serino, President and CEO of Encision Inc.

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in our filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT:        Marcia McHaffie, Encision Inc., 303-444-2600, mmchaffie@encision.com

Encision Inc.

Condensed Balance Sheets

(Amounts in thousands)

	June 30,			March 31,
	2009			2009
	(Unaudited)			(Audited)
ASSETS
Cash and cash equivalents	$	126		$	85
Accounts receivable, net		1,235			1,264
Inventories, net		2,459			2,505
Prepaid expenses		110			36
Total current assets		3,930			3,890
Equipment, net		884			840
Patents, net		223			216
Other assets		18			24
Total assets	$	5,055		$	4,970
LIABILITIES AND SHAREHOLDERS’  EQUITY
Accounts payable	$	662		$	745
Accrued compensation		311			406
Other accrued liabilities		360			367
Line of credit		275			191
Total current liabilities		1,608			1,709
Common stock and additionalpaid-in capital		19,582			19,560
Accumulated (deficit)		(16,135	)		(16,299	)
Total shareholders’ equity		3,447			3,261
Total liabilities andshareholders’equity	$	5,055		$	4,970

Encision Inc.

Condensed Statements of Operations

(Amounts in thousands, except per share information)

	(Unaudited)
	Three Months Ended
	June 30,			June 30,
	2009			2008
Net sales	$	3,174		$	3,094
Cost of sales		1,142			1,229
Gross profit		2,032			1,865
Operating expenses:
Sales and marketing		1,199			1,374
General and administrative		354			367
Research and development		301			289
Total operating expenses		1,854			2,030
Operating income (loss)		178			(165	)
Interest and other income(expense), net		(15	)		1
Income (loss) before provisionfor income taxes		163			(164	)
Provision for income taxes		–			–
Net income (loss)	$	163		$	(164	)
Net income (loss) pershare-basic and diluted	$	0.03		$	(0.03	)
Basic and diluted weightedaverage number of shares		6,455			6,450

CONTACT:  Marcia McHaffie of  Encision Inc., +1-303-444-2600, mmchaffie@encision.com